This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation 596/2014 which is part of English Law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.
28 April 2022
BEXIMCO PHARMACEUTICALS LTD.
Q3 Financial Results
Beximco Pharmaceuticals Limited ("Beximco Pharma", "BPL" or "the Company"; AIM Symbol: BXP, LEI No.: 213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, announces its unaudited financial results for the third quarter and nine months ended 31 March 2022.
Financial highlights
Nine months ended 31 March 2022 (consolidated)
· Net revenue increased 19.1% to Bangladesh Taka ("BDT") 25,928.5m / £229.1m (2020-21: BDT 21,762.4m / [£186.8.0m])
· Profit after tax increased 13.7% to BDT 4,201.2m / £37.1m (2020-21: BDT 3,695.3m / £31.7m)
Third quarter ended 31 March 2022 (consolidated)
· Net revenue increased 21.7% to BDT 8,959.6m / £79.2m (2020-21: BDT 7,362.3m / £63.2m)
· Profit after tax decreased 27.2% to BDT 1,069.3 m / £9.4m (2020-21: BDT 1,468.9m / £12.6m) due to non-recurring vaccine income in Q3 2021
Additionally, the Company announces that, under its agreement with the Government of Bangladesh and the Serum Institute of India Private Limited, Beximco Pharma has now delivered a total of 15 million Covid-19 vaccine doses. There are 15 million doses remaining under the agreement. The Company expects any further doses to be delivered in the next financial year.
Nazmul Hassan MP, Managing Director of Beximco Pharmaceuticals, commented:
"We are pleased with our continued strong financial position at the end of the third quarter, with double-digit growth YoY for the nine-month period in both revenue and profit after tax. This has been underpinned by positive operational developments such as the receipt of sublicenses to produce generic versions of molnupiravir and Paxlovid from the United Nations-backed Medicines Patent Pool and the ongoing integration of Sanofi Bangladesh, which has now been renamed Synovia Pharma PLC. We look forward to continuing this positive momentum into the final quarter as we continue to execute on our mission to provide patients with affordable, high-quality medicines."
The detailed accounts can be viewed in the Company's website www.beximcopharma.com
(Exchange rates of £1 = Taka 113.19 for 31 March 2022 numbers and £1 = Taka 116.51 for 31 March 2021 have been used in this announcement.)
For further information please visit www.beximcopharma.com or enquire to:
Beximco Pharma
Nazmul Hassan MP, Managing Director
Tel: +880 2 58611001, Ext.20080
S M Rabbur Reza, Chief Operating Officer
Tel: +880 2 58611001, Ext.20111
Mohammad Ali Nawaz, Chief Financial Officer
Tel: +880 2 58611001, Ext.20030
Jamal Ahmed Choudhury, Director, Accounts & Finance
Tel: +880 2 58611001, Ext.20022
SPARK Advisory Partners Limited (Nominated Adviser)
Mark Brady / Andrew Emmott
Tel: +44 (0) 20 3368 3551 / 3555
SP Angel Corporate Finance LLP (Broker)
Vadim Alexandre / Abigail Wayne
Tel: +44 (0) 20 3470 0470
FTI Consulting
Simon Conway / Victoria Foster Mitchell
Tel: +44 (0) 20 3727 1000
Notes to Editors
About Beximco Pharmaceuticals Limited
Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Since its inception in 1976, the Company remains committed to health and wellbeing of people across all the continents by providing access to contemporary medicines. Company's broad portfolio of generics encompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies.
Beximco Pharma′s state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others and it has a geographic footprint in more than 50 countries. More than 5,500 employees are driving the company towards achieving its aspiration to be among the most admired companies in the world.
Beximco Pharmaceuticals Limited and its Subsidiaries
Consolidated Statement of Financial Position (Un-audited)
As at March 31, 2022
|
|
|
|
|
| Taka '000 | ||
|
|
|
|
|
|
| ||
|
|
| March 31, 2022 |
|
June 30, 2021 | |||
| ASSETS |
|
|
|
|
| ||
| Non-Current Assets |
| 47,300,513 |
| 38,475,238 | |||
| Property, Plant and Equipment- Carrying Value |
|
| 41,546,339 |
| 36,211,376 | ||
| Right-of-use Assets |
|
| 491,586 |
| 319,885 | ||
| Intangible Assets |
|
| 4,507,775 |
| 1,380,694 | ||
| Deferred Tax Asset |
|
| 52,975 |
| - | ||
| Goodwill |
|
| 674,571 |
| 546,691 | ||
| Other Investments |
|
| 27,267 |
| 16,592 | ||
| Current Assets |
| 17,852,167 |
| 13,770,846 | |||
| Inventories |
|
| 9,862,206 |
| 7,142,863 | ||
| Spares & Supplies |
|
| 762,079 |
| 661,723 | ||
| Accounts Receivable |
|
| 4,132,539 |
| 2,873,845 | ||
| Loans, Advances and Deposits |
|
| 2,339,980 |
| 2,416,948 | ||
| Advance Income Tax |
|
| 166,319 |
| - | ||
| Cash and Cash Equivalents |
|
| 589,044 |
| 675,467 | ||
|
|
|
|
|
|
| ||
|
|
|
|
|
|
| ||
| TOTAL ASSETS |
| 65,152,680 |
| 52,246,084 | |||
| SHAREHOLDERS' EQUITY AND LIABILITIES |
|
|
|
|
| ||
|
|
|
|
|
| |||
| Equity Attributable to the Owners of the Company |
| 39,761,370 |
| 37,030,559 | |||
| Issued Share Capital |
|
| 4,461,121 |
| 4,461,121 | ||
| Share Premium |
|
| 5,269,475 |
| 5,269,475 | ||
| Excess of Issue Price over Face Value of GDRs |
|
| 1,689,637 |
| 1,689,637 | ||
| Capital Reserve on Merger |
|
| 294,951 |
| 294,951 | ||
| Revaluation Surplus |
|
| 1,118,129 |
| 1,121,825 | ||
| Unrealized Gain/(Loss) |
|
| 24,443 |
| 13,767 | ||
| Retained Earnings |
|
| 26,903,614 |
| 24,179,783 | ||
| Non-Controlling Interest |
| 4,080,755 |
| 334,307 | |||
| TOTAL EQUITY |
| 43,842,125 |
| 37,364,866 | |||
| Non-Current Liabilities |
| 8,841,975 |
| 5,531,540 | |||
| Long Term Borrowings-Net of Current Maturity |
|
| 3,712,933 |
| 1,206,717 | ||
| Liability for Gratuity and WPPF & Welfare Funds |
|
| 2,886,640 |
| 2,335,257 | ||
| Deferred Tax Liability |
|
| 2,242,402 |
| 1,989,566 | ||
| Current Liabilities and Provisions |
| 12,468,580 |
| 9,349,678 | |||
| Short Term Borrowings |
|
| 6,100,556 |
| 5,023,181 | ||
| Long Term Borrowings-Current Maturity |
|
| 2,016,830 |
| 1,401,406 | ||
| Creditors and Other Payables |
|
| 2,919,327 |
| 1,965,048 | ||
| Accrued Expenses |
|
| 837,160 |
| 619,399 | ||
| Dividend Payable / Unclaimed Dividend |
|
| 99,823 |
| 118,138 | ||
| Income Tax Payable |
|
| 494,884 |
| 222,506 | ||
|
|
|
|
|
|
| ||
| TOTAL EQUITY AND LIABILITIES |
| 65,152,680 |
| 52,246,084 | |||
|
|
|
|
|
|
| ||
Beximco Pharmaceuticals Limited and its Subsidiaries
Consolidated Statement of Profit or Loss and Other Comprehensive Income (Un-audited)
For the Period July 2021 -March 2022
|
|
|
|
|
|
|
|
|
|
|
| Taka '000 |
|
|
| July 2021- |
|
| July 2020- |
|
| January- |
|
| January- |
|
|
| March 2022 |
|
| March 2021 |
|
| March 2022 |
|
| March 2021 |
| Net Revenue |
| 25,928,465 | 21,762,492 | 8,959,561 | 7,362,303 | ||||||
| Cost of Goods Sold |
| (13,709,232) | (11,488,046) | (4,909,975) | (3,919,447) | ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
| Gross Profit |
| 12,219,233 | 10,274,446 | 4,049,586 | 3,442,856 | ||||||
| Operating Expenses |
| (6,499,068) | (5,074,824) | (2,263,642) | (1,710,102) | ||||||
| Administrative Expenses |
| (888,247) |
| (624,769) |
| (314,408) |
| (221,137) | |||
| Selling, Marketing and Distribution Expenses |
| (5,610,821) |
| (4,450,055) |
| (1,949,234) |
| (1,488,965) | |||
| Profit from Operations |
| 5,720,165 |
| 5,199,622 |
| 1,785,944 |
| 1,732,754 | |||
| Other Income |
| 974,419 | 658,780 | 172,447 | 488,867 | ||||||
| Finance Cost |
| (709,894) | (667,381) | (277,537) | (164,526) | ||||||
| Profit Before Contribution to WPPF & Welfare Funds |
|
|
|
|
|
|
|
|
|
|
|
|
| 5,984,690 | 5,191,021 | 1,680,854 | 2,057,095 | |||||||
| Contribution to WPPF & Welfare Funds |
| (300,555) | (250,375) | (84,745) | (98,460) | ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
| Profit Before Tax |
| 5,684,135 | 4,940,646 | 1,596,109 | 1,958,635 | ||||||
| Income Tax Expenses |
| (1,482,958) | (1,245,355) | (526,803) | (489,643) | ||||||
| Current Tax |
| (1,244,950) |
| (1,190,941) |
| (247,863) |
| (463,289) | |||
| Deferred Tax |
| (238,008) |
| (54,414) |
| (278,940) |
| (26,354) | |||
| Profit After Tax |
|
|
|
|
|
|
|
| |||
|
| 4,201,177 | 3,695,291 | 1,069,306 | 1,468,992 | |||||||
| Profit/(Loss) Attributable to: |
|
|
|
|
|
|
|
|
|
|
|
| Owners of the Company |
| 4,280,454 |
| 3,670,643 |
| 1,102,438 |
| 1,461,959 | |||
| Non-controlling interest |
| (79,277) |
| 24,648 |
| (33,132) |
| 7,033 | |||
|
|
| 4,201,177 | 3,695,291 | 1,069,306 | 1,468,992 | ||||||
| Other Comprehensive Income-Unrealized Gain/(Loss) |
| 10,676 | 10,776 | 789 | 3,273 | ||||||
| Total Comprehensive Income |
| 4,211,853 |
|
| 3,706,067 |
|
| 1,070,095 |
|
| 1,472,265 |
| Total Comprehensive Income Attributable to: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
| Owners of the Company |
| 4,291,130 |
| 3,681,419 |
| 1,103,227 |
| 1,465,232 | |||
| Non-controlling interest |
| (79,277) |
| 24,648 |
| (33,132) |
| 7,033 | |||
|
|
| 4,211,853 |
| 3,706,067 |
| 1,070,095 |
| 1,472,265 | |||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Earnings Per Share (EPS)/Restated EPS |
| 9.60 | 8.23 | 2.47 | 3.28 | ||||||
| Number of Shares Used to Compute EPS | Nos. | 446,112,089 | 446,112,089 | 446,112,089 | 446,112,089 | ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
Beximco Pharmaceuticals Limited and its Subsidiaries
Consolidated Statement of Changes in Equity (Un-audited)
For the Period July 2021 -March 2022
| As at March 31, 2022 |
|
|
|
|
|
|
|
|
|
|
| Taka' 000 | |
|
|
| Share | Share | Excess of | Capital | Revaluation | Unrealized | Retained |
|
| Equity | Non- | Total |
|
|
| Capital | Premium | Issue | Reserve on | Surplus | Gain/(Loss) | Earnings |
| attributable | Controlling | Equity | |
|
|
|
|
| Price over | Merger |
|
|
|
|
| to the | Interests |
|
|
|
|
|
| Face Value |
|
|
|
|
|
| Owners |
|
|
|
|
|
|
| of GDRs |
|
|
|
|
|
| of the |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
| Balance as on July 01, 2021 | 4,461,121 | 5,269,475 | 1,689,637 | 294,951 | 1,121,825 | 13,767 | 24,179,783 |
|
| 37,030,559 | 334,307 | 37,364,866 | |
| NCI at the date of acquisition-SPP | - | - | - | - | - | - | - |
|
| - | 3,857,135 | 3,857,135 | |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
| Total Comprehensive Income: |
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Profit/(Loss) for the Period |
| - | - | - | - | - | - | 4,280,454 |
|
| 4,280,454 | (79,277) | 4,201,177 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
| Other Comprehensive Income/(Loss) | - | - | - | - | - | 10,676 | - |
|
| 10,676 | - | 10,676 | |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
| Transactions with the Shareholders: |
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cash Dividend |
| - | - | - | - |
| - | (1,561,392) |
|
| (1,561,392) | (31,410) | (1,592,802) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Adjustment for Depreciation on Revalued Assets | - | - | - | - | (4,769) | - | 4,769 |
|
| - | - | - | |
|
|
|
|
|
|
|
|
|
|
|
|
| ||
| Adjustment for Deferred Tax on Revalued Assets | - | - | - | - | 1,073 | - | - |
|
| 1,073 | - | 1,073 | |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
| Balance as on March 31, 2022 | 4,461,121 | 5,269,475 | 1,689,637 | 294,951 | 1,118,129 | 24,443 | 26,903,614 |
|
| 39,761,370 | 4,080,755 | 43,842,125 | |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
| Number of Shares |
|
|
|
|
|
|
|
| 446,112,089 |
|
| ||
| Net Asset Value (NAV) Per Share |
|
|
|
|
|
|
| Tk. | 89.13 |
|
| ||
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
| As at March 31, 2021 |
|
|
|
|
|
|
|
|
|
|
| Taka' 000 | |
|
|
| Share | Share | Excess of | Capital | Revaluation | Unrealized | Retained |
|
| Equity | Non- | Total |
|
|
| Capital | Premium | Issue | Reserve on | Surplus | Gain/(Loss) | Earnings |
| attributable | Controlling | Equity | |
|
|
|
|
| Price over | Merger |
|
|
|
|
| to the | Interests |
|
|
|
|
|
| Face Value |
|
|
|
|
|
| Owners |
|
|
|
|
|
|
| of GDRs |
|
|
|
|
|
| of the |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
| Balance as on July 01, 2020 | 4,055,564 | 5,269,475 | 1,689,637 | 294,951 | 1,125,768 | 926 | 20,058,800 |
|
| 32,495,121 | 302,329 | 32,797,450 | |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
| Total Comprehensive Income: |
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Profit/(Loss) for the Period |
| - | - | - | - | - | - | 3,670,643 |
|
| 3,670,643 | 24,648 | 3,695,291 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
| Other Comprehensive Income/(Loss) | - | - | - | - | - | 10,776 | - |
|
| 10,776 | - | 10,776 | |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
| Transactions with the Shareholders: |
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cash Dividend |
|
| - | - | - | - | - | (608,335) |
|
| (608,335) | (6,078) | (614,413) |
| Stock Dividend |
| 405,557 | - | - | - | - | - | (405,557) |
|
| - | - | - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Adjustment for Depreciation on Revalued Assets |
| - | - | - | (5,385) | - | 5,385 |
|
|
| - | - | |
| Adjustment for Deferred Tax on Revalued Assets |
| - | - | - | 1,346 | - | - |
|
| 1,346 | - | 1,346 | |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
| Balance as on March 31, 2021 | 4,461,121 | 5,269,475 | 1,689,637 | 294,951 | 1,121,729 | 11,702 | 22,720,936 |
|
| 35,569,551 | 320,899 | 35,890,450 | |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
| Number of Shares |
|
|
|
|
|
|
|
| 446,112,089 |
|
| ||
| Net Asset Value (NAV) Per Share |
|
|
|
|
|
|
| Tk. | 79.73 |
|
| ||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Beximco Pharmaceuticals Limited and its Subsidiaries
Consolidated Statement of Cash Flows (Un-audited)
For the Period July 2021 -March 2022
|
|
|
|
|
|
|
| Taka '000 | |
|
|
|
|
|
|
|
|
| |
|
|
| July 2021- |
| July 2020- | ||||
|
|
| March 2022 |
| March 2021 | ||||
| Cash Flows from Operating Activities : |
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
| |
| Receipts from Customers and Others |
| 26,197,399 |
|
|
| 23,003,861 | ||
| Payments to Suppliers and Employees |
| (20,550,726) |
|
|
| (17,426,836) | ||
| Cash Generated from Operations |
| 5,646,673 |
|
|
| 5,577,025 | ||
| Interest Paid |
| (710,512) | (667,752) | |||||
| Interest Received |
| 2,345 | 1,844 | |||||
| Income Tax Paid |
| (975,253) | (874,544) | |||||
| Net Cash Generated from Operating Activities |
| 3,963,253 |
| 4,036,573 | ||||
| Cash Flows from Investing Activities : |
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
| |
| Acquisition of Property, Plant and Equipment |
| (1,829,104) |
|
| (1,579,680) | |||
| Intangible Assets |
| (8,391) |
|
| (8,819) | |||
| Investment in Subsidiary |
| (4,766,636) |
|
| - | |||
| Disposal of Property, Plant and Equipment |
| 17,580 |
|
| 27,089 | |||
| Dividend Received |
| 2,015 |
|
| 857 | |||
| Net Cash Used in Investing Activities |
|
|
|
|
|
|
| |
|
| (6,584,536) | (1,560,553) | ||||||
| Cash Flows from Financing Activities : |
|
|
|
|
|
|
| |
| Net Increase /(Decrease) in Long Term Borrowings |
| 3,084,250 |
| (932,338) | ||||
| Net Increase/(Decrease) in Short Term Borrowings |
| 757,682 |
| (1,231,836) | ||||
| Dividend Paid |
| (1,611,308) |
| (578,177) | ||||
| Net Cash (Used in ) / from Financing Activities |
| 2,230,624 |
| (2,742,351) | ||||
| Increase/(Decrease) in Cash and Cash Equivalents |
| (390,659) | (266,331) | |||||
| Cash and Cash Equivalents at Beginning of Period* |
| 973,964 | 635,017 | |||||
| Effect of exchange rate changes on Cash and Cash Equivalents | 5,739 | - | ||||||
| Cash and Cash Equivalents at End of Period |
| 589,044 |
|
| 368,686 | |||
| Number of Shares |
| 446,112,089 | 446,112,089 | |||||
| Net Operating Cash Flows Per Share | 8.88 | 9.05 | ||||||
* Includes cash of Synovia Pharma PLC at the date of acquisition.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.